Duopharma Biotech Bhd

Duopharma Biotech Bhd FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Duopharma Biotech Bhd (DPHARMA.KL) as of Nov 2, 2026 is 78.94 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 17.56 % — a change of 349.56% (higher).

FCF Conversion

78.94 %

YoY

349.56%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Duopharma Biotech Bhd is 2024 78.94 % . FCF Conversion Rate (FCF/EBITDA) of Duopharma Biotech Bhd was 2023 17.56 % . It decreases by 349.56% higher compared to the previous year.

The Duopharma Biotech Bhd FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
-43.66 MYR
Jan 1, 2018
-42.86 MYR
Jan 1, 2019
10.98 MYR
Jan 1, 2020
9.78 MYR
Jan 1, 2021
-109.32 MYR
Jan 1, 2022
-1.08 MYR
Jan 1, 2023
17.56 MYR
Jan 1, 2024
78.94 MYR
The Duopharma Biotech Bhd FCF Conversion history
YEARFCF ConversionYoY
78.94 %+349.56%
17.56 %-1,728.45%
-1.08 %-99.01%
-109.32 %-1,217.76%
9.78 %-10.92%
10.98 %-125.61%
-42.86 %-1.83%
-43.66 %+712.25%
-5.38 %-97.88%
-253.61 %-479.95%
66.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd Stock analysis

What does Duopharma Biotech Bhd do? Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond. Duopharma Biotech Bhd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Duopharma Biotech Bhd stock

FCF Conversion Rate (FCF/EBITDA) of Duopharma Biotech Bhd is 78.94 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Duopharma Biotech Bhd changed from 17.56 % to 78.94 %, representing a 349.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Duopharma Biotech Bhd since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Duopharma Biotech Bhd with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Duopharma Biotech Bhd

All Key Metrics — Duopharma Biotech Bhd